Compare Novavax Inc (NVAX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Schlumberger NV — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Schlumberger NV trades at $46.77 (market cap $69.36B). The key difference: Schlumberger NV is far larger — about 53.4× Novavax Inc's market cap, and Schlumberger NV pays a 2.54% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SLB | |
|---|---|---|
Market Cap | $1.30B | $69.36B |
Sector | Health | Energy |
52-Week High | $11.19 | $58.01 |
52-Week Low | $6.22 | $31.72 |
Enterprise Value | $800.50M | $77.58B |
Dividend Yield | — | 2.54% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
